KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Other Non-Current Assets (2016 - 2023)

Palvella Therapeutics has reported Other Non-Current Assets over the past 8 years, most recently at $1.4 million for Q4 2022.

  • Quarterly Other Non-Current Assets fell 52.86% to $1.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2022, down 52.86% year-over-year, with the annual reading at $1.4 million for FY2022, 52.86% down from the prior year.
  • Other Non-Current Assets was $1.4 million for Q4 2022 at Palvella Therapeutics, up from $1.3 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $11.5 million in Q2 2019 and troughed at $121000.0 in Q3 2018.
  • The 5-year median for Other Non-Current Assets is $2.2 million (2020), against an average of $2.7 million.
  • Year-over-year, Other Non-Current Assets skyrocketed 8806.98% in 2019 and then tumbled 82.81% in 2020.
  • A 5-year view of Other Non-Current Assets shows it stood at $910000.0 in 2018, then soared by 245.71% to $3.1 million in 2019, then grew by 5.18% to $3.3 million in 2020, then fell by 12.24% to $2.9 million in 2021, then plummeted by 52.86% to $1.4 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Other Non-Current Assets are $1.4 million (Q4 2022), $1.3 million (Q3 2022), and $2.4 million (Q2 2022).